Steven Ryder - 29 Oct 2026 Form 4 Insider Report for Yarrow Bioscience, Inc. (YARW)

Reporting relationship: Chief Medical Officer
Issuer ticker: YARW
Reported as of: 29 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Oct 2026, 16:02:22 UTC
Prior SEC filing: 29 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Tyler Zeronda, as attorney-in-fact for Steven Ryder

Filing notes and source

Key filing fact

Steven Ryder filed Form 4 for Yarrow Bioscience, Inc. (YARW) on 30 Oct 2026.

Key facts

This page summarizes Steven Ryder's Form 4 filing for Yarrow Bioscience, Inc. (YARW).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Oct 2026, 16:02.

Change

Previous filing in this sequence was filed on 29 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001872868 Primary reporting owner

Ryder Steven

Relationship: Chief Medical Officer
Address: C/O YARROW BIOSCIENCE, INC., 470 JAMES STREET, SUITE 007, NEW HAVEN
Signature: /s/ Tyler Zeronda, as attorney-in-fact for Steven Ryder
Signature date: 30 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

YARW transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +113,137
Change %
Price: $0.000000^*
Shares after: 113,137
Date: 29 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 113,137
Exercise price: $20.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase 113,137 shares of the Issuer's common stock, one quarter of which will vest on July 28, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.